The think tank argues regulated compounding beats 'research use only' sellers, noting an FDA panel voted to add six peptides despite staff advising against all seven.
Recap by typeshit. Full story at Reason Foundation.
In a JAMA Viewpoint, CSPI authors argue a peptide-friendly advisory panel stacked with industry-tied members threatens drug approval integrity.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
NSW peptide hospitalisations went from five in July 2025 to over 200 in September 2026, and needle programs say syringe machines are emptying within hours.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Loading…